The global aspirin exacerbated respiratory disease market size is expected to reach US$ 8.7 Billion in 2032 and exhibit growth at a CAGR of 4.9% in the forecast period from 2022 to 2032. As per the report, sales of treatment options for aspirin exacerbated respiratory disease is likely to exceed US$ 3.1 Billion in 2022. The increasing number of research and development activities to discover novel treatment options are anticipated to boost the market.
| Report Attribute | Details |
| Aspirin Exacerbated Respiratory Disease Market Estimated Base Year Value (2021) | US$ 2.5 Billion |
| Aspirin Exacerbated Respiratory Disease Market Expected Market Value (2022) | US$ 3.1 Billion |
| Aspirin Exacerbated Respiratory Disease Market Anticipated Forecast Value (2032) | US$ 8.7 Billion |
| Aspirin Exacerbated Respiratory Disease Market Projected Growth Rate (2022-2032) | 4.9% CAGR |
Aspirin-exacerbated respiratory disease or Samter’s Triad is a chronic medical condition that includes three clinical features, namely, sensitivity to aspirin, sinus disease with recurrent nasal polyps, and asthma. Signs and symptoms of this disease do not usually show up until an individual reaches their 30s or 40s.
Some of the signs and symptoms include sneezing, difficulty breathing, runny nose, coughing, or wheezing. Some people living with aspirin-exacerbated respiratory disease often get these types of reactions if they drink alcoholic beverages, such as wine or beer.
There is no specific test to diagnose the disease. Laboratory tests, such as blood tests help in looking for higher than normal levels of eosinophils, which are white blood cells. Healthcare professionals often recommend urine tests to observe inflammatory substances and elevated leukotrienes in the body.
Increasing prevalence of breathing problems, such as asthma is anticipated to augur well for the global market. As per the World Health Organization (WHO), nearly 262 million people were living with asthma in 2019 and it had caused 461000 deaths. These numbers are projected to grow at a fast pace, thereby pushing the demand for aspirin exacerbated respiratory disease treatment options.
Moreover, surging awareness programs conducted by government agencies to educate the masses about the signs and symptoms of this disease is set to drive the market. Rising healthcare expenditure in both developed and developing countries across the globe is another vital factor that is likely to fuel the market.
The diagnosis of aspirin exacerbated respiratory disease can often be delayed unless healthcare professionals have experience or expertise in recognizing and treating it. Thus, the lack of skilled healthcare professionals across emerging economies is projected to hamper the aspirin exacerbated respiratory disease market growth in future years.
North America is likely to remain at the forefront by procuring the largest aspirin exacerbated respiratory disease market share in the upcoming years. The presence of numerous large-scale pharmaceutical companies in the U.S. and Canada is projected to augur well for the regional market.
The increasing consumption of zileuton (Zyflo) or montelukast (Singulair) to block the effects of leukotrienes across North America is also set to propel the market. In addition to that, patients are increasingly adopting medications, such as inhaled corticosteroids to manage asthma and it is further expected to augment the market.
Asia Pacific is likely to remain in the second position followed by North America in terms of share during the evaluation period. Rising prevalence of pollution induced asthma and the ongoing development of healthcare infrastructure in China and India are anticipated to drive the sales of aspirin exacerbated respiratory disease treatment medications.
Besides, the entry of international pharmaceutical companies in these countries owing to the availability of low-cost labor and raw material is expected to foster growth. The availability of innovative injectable medications, commonly called biologics, would also contribute to the regional market growth.
Some of the renowned companies operating in the global aspirin exacerbated respiratory disease market include Apotex Corporation, Pfizer Inc., Teva Pharmaceuticals, Zydus Pharmaceuticals, and Cadila Pharmaceuticals among others.
Majority of the leading companies present in the global market are increasingly focusing on mergers and acquisitions, collaborations, and joint ventures to co-develop novel products and strengthen their positions. Meanwhile, a few other key players are aiming to invest huge sums for conducting clinical trials to develop state-of-the-art medications.
| Report Attribute | Details |
| Growth Rate | CAGR of 4.9% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2015-2020 |
| Forecast Period | 2022-2032 |
| Quantitative Units | Revenue in USD Billion, Volume in Kilotons and CAGR from 2022-2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
By Product Type:
Route of Administration:
By Distribution Channel:
By Region:
The global aspirin exacerbated respiratory disease market is projected to exceed US$ 8.7 Billion in 2032.
North America is expected to dominate the aspirin exacerbated respiratory disease market in the near future.
Apotex Corporation, Pfizer Inc., Teva Pharmaceuticals, Zydus Pharmaceuticals, and Cadila Pharmaceuticals are some of the leading companies in the aspirin exacerbated respiratory disease market.
Explore Similar Insights
Aspirin Exacerbated Respiratory Disease Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
Chat With
MaRIA
